Phoenix Bio

R&D OVERVIEW

R&D OVERVIEW

Characterization of HBV integration patterns and timing in liver cancer and HBV-infected livers

    Furuta, M. Tanaka, H. Shiraishi, Y. Unida, T. mamura, M. Fujimoto, A. Fujita, M. Sasaki-Oku, A. Maejima, K. Nakano, K. Kawakami, Y. Arihiro, K. Aikata, H. Ueno, M. Hayami, S. Ariizumi, S. I. Yamamoto, M. Gotoh, K. Ohdan, H. Yamaue, H. Miyano, S. Chayama, K. Nakagawa, H.

    Oncotarget. 2018 May 18;9(38):25075-25088.

    Rosmarinic acid is a novel inhibitor for Hepatitis B virus replication targeting viral epsilon RNA-polymerase interaction

      Tsukamoto, Y. Ikeda, S. Uwai, K. Taguchi, R. Chayama, K. Sakaguchi, T. Narita, R. Yao, W. L. Takeuchi, F. Otakaki, Y. Watashi, K. Wakita, T. Kato, H. Fujita, T.

      PLoS One. 2018 May 21;13(5):e0197664.

      Identifying and Characterizing Interplay between Hepatitis B Virus X Protein and Smc5/6

        Livingston, C. M. Ramakrishnan, D. Strubin, M. Fletcher, S. P. Beran, R. K.

        Viruses. 2017 Apr 3;9(4). pii: E69. doi: 10.3390/v9040069.

        Acute HBV infection in humanized chimeric mice has multiphasic viral kinetics

          Ishida, Y. Chung, T. L. Imamura, M. Hiraga, N. Sen, S. Yokomichi, H. Tateno, C. Canini, L. Perelson, A. S. Uprichard, S. L. Dahari, H. Chayama, K.

          Hepatology. 2018 Mar 23. doi: 10.1002/hep.29891.

          Investigating the hepatitis B virus life cycle using engineered reporter hepatitis B viruses

            Nishitsuji, H. Harada, K. Ujino, S. Zhang, J. Kohara, M. Sugiyama, M. Mizokami, M. Shimotohno, K.

            Cancer Sci. 2018 Jan;109(1):241-249.

            A Novel Orally Available Small Molecule That Inhibits Hepatitis B Virus Expression

              Mueller, H. Wildum, S. Luangsay, S. Walther, J. Lopez, A. Tropberger, P. Ottaviani, G. Lu, W. John Parrott, N. Zhang, J. D. Schmucki, R. Racek, T. Hoflack, J. C. Kueng, E. Point, F. Zhou, X. Steiner, G. Lutgehetmann, M. Rapp, G. Volz, T. Dandri, M. Yang, S. Young, J. A. T. Javanbakht, H.

              J Hepatol. 2017 Oct 24. pii: S0168-8278(17)32393-0. doi: 10.1016/j.jhep.2017.10.014.

              Efficacy of NVR 3-778, Alone and in Combination With Pegylated Interferon, vs Entecavir in uPA/SCID Mice With Humanized Livers and HBV Infection

                Klumpp, K. Shimada, T. Allweiss, L. Volz, T. Lutgehetmann, M. Hartman, G. Flores, O. A. Lam, A. M. Dandri, M.

                Gastroenterology. 2017 Oct 24. pii: S0016-5085(17)36276-5. doi: 10.1053/j.gastro.2017.10.017.

                Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus

                  Sato, Y. Matsui, H. Yamamoto, N. Sato, R. Munakata, T. Kohara, M. Harashima, H.

                  J Control Release. 2017 Oct 3;266:216-225. doi: 10.1016/j.jconrel.2017.09.044.

                  Hepatitis B virus evades innate immunity of hepatocytes but activates cytokine production by macrophages

                    Cheng, X. Xia, Y. Serti, E. Block, P. D. Chung, M. Chayama, K. Rehermann, B. Liang, T. J.

                    Hepatology. 2017 Jun 30. doi: 10.1002/hep.29348.

                    Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus

                      Tsuge, M. Uchida, T. Hiraga, N. Kan, H. Makokha, G. N. Abe-Chayama, H. Miki, D. Imamura, M. Ochi, H. Hayes, C. N. Shimozono, R. Iwamura, T.Narumi, H. Suzuki, T  Kainoh, M. Taniguchi, T. Chayama, K.

                      Antimicrob Agents Chemother. 2017 May 24;61(6).